Sessa Capital’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Sessa Capital’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,879,023	Closed	-$214M	–	39
2023 Q1	$214M	Sell	8,879,023 -6,000,000	-40%	-$75.3M	8.12%	3
2022 Q4	$157M	Hold	14,879,023	–	–	9.67%	4
2022 Q3	$67M	Buy	14,879,023 +8,879,023	+148%	+$40.5M	4.78%	8
2022 Q2	$24M	Hold	6,000,000	–	–	1.31%	16
2022 Q1	$43.9M	Buy	6,000,000 +104,475	+2%	+$625K	2.1%	14
2021 Q4	$33.1M	Buy	5,895,525 +1,700,409	+41%	+$10.8M	1.64%	18
2021 Q3	$26.8M	Buy	4,195,116 +1,408,158	+51%	+$9.05M	1.32%	20
2021 Q2	$23.5M	Buy	+2,786,958	New	+$22.5M	0.88%	24

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sessa Capital's PRVB Position: Q2 2023 in Review

Sessa Capital sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 8,879,023 shares — an estimated $214M sold.

Sessa Capital first reported a position in PRVB in Q2 2021 and held it in 8 quarters. The position peaked at $214M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Sessa Capital reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Sessa Capital sold 8,879,023 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $214M.
Sessa Capital first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Sessa Capital's Provention Bio, Inc. Common Stock position peaked at $214M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Sessa Capital's 13F filing for Q2 2023, filed 14 Aug 2023.